ATYR
insider transactionsaTYR PHARMA INC — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
+93.6K
100.0K buy · 6.4K sell
Net value · 365d
$43.4K
$49.6K in · $6.3K out
Sentiment · 365d
Net buying
89% buying · 11% selling
Open-market trades · 365d
4
100.0K buy · 6.4K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Buy·P
Director
$49.6K
100.0K sh · $0.50
Own +15%
-
Grant·A
Director
$0
50.0K sh
Own New
-
Grant·A
Director
$0
50.0K sh
Own New
-
Grant·A
Director
$0
50.0K sh
Own New
-
Grant·A
Director
$0
50.0K sh
Own New
-
Grant·A
Director
$0
50.0K sh
Own New
-
Grant·A
Chief Commercial Officer
$0
6.4K sh
Own New
-
Grant·A
Chief Commercial Officer
$0
36.3K sh
Own New
-
Exercise·M
Chief Commercial Officer
$0
2.1K sh
Own New
-
Exercise·M
Chief Commercial Officer
$0
2.0K sh
Own +100%
-
Other·F
Chief Commercial Officer
$1.1M
9.0K sh · $124.12
Own -12%
-
Grant·A
Chief Commercial Officer
$0
16.6K sh
Own +30%
-
Other·F
Chief Commercial Officer
$139.5K
1.1K sh · $124.12
Own -2%
-
Exercise·M
Chief Commercial Officer
$0
2.1K sh
Own +4%
-
Other·F
Chief Commercial Officer
$131.3K
1.1K sh · $124.12
Own -2%
-
Exercise·M
Chief Commercial Officer
$0
2.0K sh
Own +4%
-
Exercise·M
Chief Commercial Officer
$0
2.0K sh
Own +50%
-
Other·F
Chief Commercial Officer
$133.2K
1.1K sh · $123.10
Own -2%
-
Exercise·M
Chief Commercial Officer
$0
2.0K sh
Own +4%
-
Sell·S
Sanjay Shukla KEY
President and CEO
$3.7K
3.7K sh · $0.98
Own -2%
-
Sell·S
General Counsel
$1.1K
1.1K sh · $0.98
Own -3%
-
Sell·S
Chief Financial Officer
$1.5K
1.6K sh · $0.98
Own -4%
-
Exercise·M
Sanjay Shukla KEY
President and CEO
$0
10.4K sh
Own New
-
Exercise·M
Sanjay Shukla KEY
President and CEO
—
10.4K sh
Own +7%
-
Exercise·M
General Counsel
$0
2.7K sh
Own New
-
Exercise·M
General Counsel
—
2.7K sh
Own +9%
-
Exercise·M
Chief Financial Officer
$0
3.8K sh
Own New
-
Exercise·M
Chief Financial Officer
—
3.8K sh
Own +11%
-
Exercise·M
Chief Commercial Officer
$0
2.3K sh
Own New
-
Other·F
Chief Commercial Officer
$175.8K
1.3K sh · $136.06
Own -2%
-
Exercise·M
Chief Commercial Officer
$0
2.3K sh
Own +4%
-
Grant·A
Sanjay Shukla KEY
President and CEO
$0
1.5M sh
Own New
-
Grant·A
General Counsel
$0
412.5K sh
Own New
-
Grant·A
Chief Financial Officer
$0
412.5K sh
Own New
-
Grant·A
Director
$0
24.4K sh
Own New
-
Exercise·M
Chief Commercial Officer
$0
12.8K sh
Own New
-
Exercise·M
Chief Commercial Officer
$461.8K
12.8K sh · $35.99
Own +29%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 27, 2026 | SCHIMMEL PAUL | Buy P | 100.0K | $49.6K |
| May 11, 2026 | Sara Zaknoen | Grant A | 50.0K | $0 |
| May 11, 2026 | SCHIMMEL PAUL | Grant A | 50.0K | $0 |
| May 11, 2026 | Svetlana Lucas | Grant A | 50.0K | $0 |
| May 11, 2026 | Jane A Gross | Grant A | 50.0K | $0 |
| May 11, 2026 | Eric Benevich | Grant A | 50.0K | $0 |
| Feb 13, 2026 | Eric Benevich | Grant A | 6.4K | $0 |
| Feb 13, 2026 | Eric Benevich | Grant A | 36.3K | $0 |
| Feb 13, 2026 | Eric Benevich | Exercise M | 2.1K | $0 |
| Feb 13, 2026 | Eric Benevich | Exercise M | 2.0K | $0 |
| Feb 13, 2026 | Eric Benevich | Other F | 9.0K | $1.1M |
| Feb 13, 2026 | Eric Benevich | Grant A | 16.6K | $0 |
| Feb 13, 2026 | Eric Benevich | Other F | 1.1K | $139.5K |
| Feb 13, 2026 | Eric Benevich | Exercise M | 2.1K | $0 |
| Feb 13, 2026 | Eric Benevich | Other F | 1.1K | $131.3K |
| Feb 13, 2026 | Eric Benevich | Exercise M | 2.0K | $0 |
| Feb 12, 2026 | Eric Benevich | Exercise M | 2.0K | $0 |
| Feb 12, 2026 | Eric Benevich | Other F | 1.1K | $133.2K |
| Feb 12, 2026 | Eric Benevich | Exercise M | 2.0K | $0 |
| Feb 4, 2026 | Sanjay Shukla KEY | Sell S | 3.7K | $3.7K |
| Feb 4, 2026 | Nancy Denyes | Sell S | 1.1K | $1.1K |
| Feb 4, 2026 | Jill Marie Broadfoot KEY | Sell S | 1.6K | $1.5K |
| Feb 3, 2026 | Sanjay Shukla KEY | Exercise M | 10.4K | $0 |
| Feb 3, 2026 | Sanjay Shukla KEY | Exercise M | 10.4K | — |
| Feb 3, 2026 | Nancy Denyes | Exercise M | 2.7K | $0 |
| Feb 3, 2026 | Nancy Denyes | Exercise M | 2.7K | — |
| Feb 3, 2026 | Jill Marie Broadfoot KEY | Exercise M | 3.8K | $0 |
| Feb 3, 2026 | Jill Marie Broadfoot KEY | Exercise M | 3.8K | — |
| Jan 31, 2026 | Eric Benevich | Exercise M | 2.3K | $0 |
| Jan 31, 2026 | Eric Benevich | Other F | 1.3K | $175.8K |
| Jan 31, 2026 | Eric Benevich | Exercise M | 2.3K | $0 |
| Jan 9, 2026 | Sanjay Shukla KEY | Grant A | 1.5M | $0 |
| Jan 9, 2026 | Nancy Denyes | Grant A | 412.5K | $0 |
| Jan 9, 2026 | Jill Marie Broadfoot KEY | Grant A | 412.5K | $0 |
| Jan 2, 2026 | Jill Marie Broadfoot | Grant A | 24.4K | $0 |
| Nov 28, 2025 | Eric Benevich | Exercise M | 12.8K | $0 |
| Nov 28, 2025 | Eric Benevich | Exercise M | 12.8K | $461.8K |
About ATYR insider trading
This page tracks insider transactions for aTYR PHARMA INC (ATYR) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.